<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>29031</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_pmc">29031</infon><infon key="article-id_pmid">11056740</infon><infon key="article-id_publisher-id">cc-3-6-151</infon><infon key="fpage">151</infon><infon key="issue">6</infon><infon key="journal-title">Critical Care</infon><infon key="kwd">APACHE II score bleeding case-control study intensive care unit mortality prognosis sepsis transfusion thrombocytopenia underlying disease</infon><infon key="lpage">158</infon><infon key="name_0">surname:Stephan;given-names:François</infon><infon key="name_1">surname:Montblanc;given-names:Jacques de</infon><infon key="name_2">surname:Cheffi;given-names:Ali</infon><infon key="name_3">surname:Bonnet;given-names:Francis</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">3</infon><infon key="year">1999</infon><offset>0</offset><text>Thrombocytopenia in critically ill surgical patients: a case-control 		  study evaluating attributable mortality and transfusion requirements</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>142</offset><text>Background:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>154</offset><text>That thrombocytopenia results in increased mortality or 				transfusion requirements has not been confirmed by previous studies. We 				performed a case-control study in which 36 patients who developed severe 				thrombocytopenia of less than 50×109 platelets/l were carefully 				matched for the severity of underlying disease and other important 				variables.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>518</offset><text>Results:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>527</offset><text>Seventeen (47%) thrombocytopenic patients died, versus 10 (28%) 				matched control patients who were not thrombocytopenic.Nine pairs had a 				discordant outcome, and in eight of these pairs the thrombocytopenic patient 				died (exact binomial probability 0.037). The estimated attributable mortality 				was 19.5% (95% confidence interval 3.2⌓35.8), and the estimated odds ratio was 				2.7 (95% confidence interval 1.02⌓7.10). Thrombocytopenic patients had 				comparable values for severity of illness scores between day of admission and 				day of thrombocytopenia, in contrast with control patients who had a 				statistically significant decrease in severity of illness scores during the 				same period. Thirty (83%) of the thrombocytopenic patients required transfusion 				of blood products, versus 21 (58%) control patients (paired χ2 				test 4.92, P &lt; 0.04). The estimated attributable transfusion 				requirement was 25% (95% confidence interval 5.4⌓44.6), and the estimated odds 				ratio was 1.52 (95 confidence interval 1.05⌓2.20).</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1586</offset><text>Conclusion:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1598</offset><text>The present study suggests that thrombocytopenia of less than 				50 × 109 platelets/l may be a marker for more severe illness and 				increased risk of death, rather than causative, because a true causal 				relationship is not established. Thrombocytopenia also leads to an excess of 				blood product consumption.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1916</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1929</offset><text>Thrombocytopenia is a well known complication in intensive care unit 		  (ICU) patients. It has been associated with various risk factors, but mainly 		  with sepsis. The incidence of thrombocytopenia of less than 		  100 × 109platelets/l in ICU patients has been reported to vary 		  from 23 to 41%, but lower frequencies (10⌓17%) have been reported for counts 		  lower than 50 × 109 platelets/l. Mortality rates as high as 38⌓54% 		  have been observed, and have been reported to be proportional to the nadir of 		  the platelet count. Previous studies have not clearly demonstrated that 		  thrombocytopenia results in increased mortality or increased transfusion 		  requirements, however. Two independent factors have made this important and 		  seemingly straightforward issue difficult to resolve.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2741</offset><text>First, mortality rates are high in such patients for many reasons. 		  Numerous studies have 		  demonstrated that severe underlying illness predisposes to the development of 		  thrombocytopenia in ICU patients, and the influence of thrombocytopenia on 		  mortality is therefore difficult to assess. Although thrombocytopenia in the 		  critically ill is more often a symptom than a disease process per se, 		  it might increase mortality in several ways. Thrombocytopenia can result in a 		  mild, moderate, or severe haemorrhagic disorder, which could enhance the risk 		  of morbidity and mortality in critically ill surgical patients. The adverse effects of anaemia in such patients have also 		  recently been discussed. 		  Apart from its haemostatic effect, thrombocytopenia also increases the 		  susceptibility to and severity of certain infections. Although several studies have found a relationship 		  between thrombocytopenia and the likelihood of death, especially in septic 		  patients, 		  thrombocytopenia has rarely been identified as an independent predictive factor 		  of death using multiple logistic regression. Nevertheless, these previous 		  studies failed to reach any definite conclusions regarding whether 		  thrombocytopenia per se was responsible for the poorer prognosis, or 		  whether this higher mortality simply reflected more severe underlying 		  illness.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4139</offset><text>Second, the threshold value for severe thrombocytopenia that is 		  supposed to jeopardize the prognosis is difficult to determine. We and others 		   		  have suggested that a platelet count less than 50 × 109/l is 		  associated with a poor outcome. Moreover, guidelines for platelet transfusion have proposed that the threshold value of 		  50 × 109 platelets/l is indicative of platelet transfusion 		  requirement in surgical patients.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4582</offset><text>One of the commonest methods to evaluate excess mortality is to 		  perform a case-control study in which confounding variables (eg severity of 		  underlying illness, reason for hospitalization, and so forth) are carefully 		  matched in the two populations. To date, however, no case-control studies that 		  have evaluated morbidity and mortality associated with thrombocytopenia in ICU 		  patients have been published in which these important variables have been 		  carefully matched.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5073</offset><text>We therefore designed a case-control study to determine to what extent 		  severe thrombocytopenia (defined as &lt; 50 × 109 platelets/l) 		  increases mortality and blood product requirements in surgical ICU 		  patients.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>5294</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5302</offset><text>Study design</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5315</offset><text>We performed a matched cohort study, with a matched control patient 			 without thrombocytopenia for each thrombocytopenic patient (1:1 matching). The 			 study was conducted in the Service de Réanimation Chirurgicale of Tenon 			 University Hospital in Paris. This 8-bed ICU admits patients from all surgical 			 departments and operating rooms of the hospital. The study period ran from 			 January 1, 1996 to December 31, 1996, during which time 298 patients were 			 admitted to the ICU and thrombocytopenic patients were prospectively 			 identified.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5872</offset><text>Case identification</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5892</offset><text>Platelet count was performed daily for all patients. Patients who 			 experienced even a single episode of thrombocytopenia of less than 			 50 × 109platelets/l during the ICU stay were classified as 			 'cases'. Low platelet counts were confirmed by direct examination 			 of the blood smear. Platelet transfusions were administered to actively 			 bleeding patients and patients scheduled for emergency surgery if their 			 platelet count fell below 50 × 109/l. Likewise, platelet 			 transfusions were administered to patients at risk for bleeding complications 			 (eg postoperative patients, or after gastrointestinal bleeding) when their 			 platelet count fell below 20 × 109/l.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6581</offset><text>None of patients with a history of platelet disorders, haematologic 			 malignancies or chemotherapy, splenectomy, mechanical heart valves, or patients 			 undergoing cardiopulmonary bypass surgery were included in the patient 			 population.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6824</offset><text>Matching and selection of control patients</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6867</offset><text>Control patients had to have had no evidence of severe 			 thrombocytopenia (&lt; 50 × 109 platelets/l) at any time during 			 hospitalization in the ICU. A computer-generated list of eligible control 			 patients was obtained from a database that included 695 patients hospitalized 			 between November, 1995 and March, 1998. Control patients were selected 			 according to the following matching criteria: age (± 5 years), Acute 			 Physiology and Chronic Health Evaluation (APACHE) II score calculated on the 			 first day of ICU admission (± 5 points), primary diagnosis and duration of 			 stay in the ICU (± 5 days). The list of potential control patients was 			 reviewed for the best possible match, giving highest priority to primary 			 diagnosis, duration of stay in the ICU, APACHE II score and age. In the case of 			 multiple acceptable control patients, the one with the date of ICU admission 			 closest to that of the patient was chosen.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7823</offset><text>Collection of data</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7842</offset><text>The following information was recorded: primary diagnosis; age; sex; 			 dates of admission and discharge from the ICU; previous health status; severity 			 of underlying medical conditions stratified according to the criteria of McCabe 			 and Jackson as fatal, ultimately fatal and 			 nonfatal; first-day organ dysfunction and/or infection (ODIN) score, based on the presence or absence of cardiac, respiratory, 			 renal, hepatic, neurologic, haematologic dysfunctions and/or infection; red 			 blood cells (RBCs); fresh frozen plasma and platelet transfusion requirements; 			 and full blood count and coagulation studies (factor V assay and D-dimer 			 detection were performed only when prothrombin time was abnormal). The severity 			 of illness was evaluated with the first-day APACHE II score and the first-day new Simplified Acute Physiology Score 			 (SAPS) II.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8716</offset><text>The criteria of sepsis have previously been reported. Shock was defined as a decrease in systolic blood 			 pressure (&lt; 90 mmHg) despite adequate vascular filling or the need for 			 vasoactive drugs (dopamine &gt; 5μ g/kg per min, dobutamine, epinephrine, 			 or norepinephrine).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8995</offset><text>The definition of disseminated intravascular coagulation (DIC) 			 required the following four criteria: a platelet count less than 			 150 × 109/l; a decrease in prothrombin level activity to less 			 than 50%; a decrease in the level of factor V to less than 50%; and the 			 presence of fibrin degradation products (D-dimers).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>9326</offset><text>Statistical analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9347</offset><text>Analysis of prior data from our unit indicated that the odds ratio 			 for death was 3.9 for cases and that the mortality rate for control patients 			 was 23%. On the basis of these results, we estimated 			 that 28 patients in each group (control and case) would be required to test the 			 null hypothesis at the 0.05 significance level with a power of 0.7.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9708</offset><text>The attributable mortality due to severe thrombocytopenia was 			 defined as the crude mortality rate of the control patients subtracted from 			 that of the cases. The point estimate of the attributable mortality and 95% 			 confidence intervals (CIs) were calculated as previously described. McNemar's test with continuity correction and exact 			 binomial probabilities were used to determine whether the crude mortality rates 			 of the cases and control patients were significantly different. Because the study involved a matched cohort, the odds 			 ratio was used as a measure of relative risk. Because incidence of outcome is 			 more than 10%, correction of the odds ratio was made according to the method of 			 Zhang and Yu in order to represent better the true 			 relative risk. The 95% CI of the odds ratio was calculated using 			 Miettinen's test-based approach.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10587</offset><text>Differences in medians were tested using Wilcoxon's test for 			 continuous variables and the χ2 test for categorical variables, 			 with Yates' correction when appropriate. Quantitative data were expressed 			 as means± standard deviation. P &lt; 0.05 was considered 			 statistically significant.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>10886</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>10894</offset><text>Study population</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>10911</offset><text>During the study period, 36 of the 298 studied ICU patients 			 developed severe thrombocytopenia of less than 50 × 109 			 platelets/l, producing a global incidence rate of 12 episodes of 			 thrombocytopenia per 100 admissions. Thrombocytopenia occurred 3.2 ± 4.8 			 days (median 2 days, interquartile range 2.5 days, range 0⌓26 days) after ICU 			 admission, for a mean duration of 3.4 ± 2.9 days (median 2 days, 			 interquartile range 4 days, range 1⌓13 days). Thrombocytopenia was related to 			 sepsis in eight patients; sepsis and DIC in 11 patients; bleeding in nine 			 patients; bleeding and DIC in six patients; undetermined shock and DIC in one 			 patient; and haemolysis-elevated liver enzymes-low platelets syndrome with DIC 			 in one patient. Matching was performed for these 36 patients.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11726</offset><text>On admission to ICU, the mean platelet count was 127 ± 			 75 × 109/l (median 116) versus 199 ± 			 123 × 109/l (median 161) in cases and control patients, 			 respectively (not significant). During ICU stay, mean nadir platelet count was 			 28 ± 14 × 109/l (median 29.5) versus 184 ± 			 142 × 109/l (median 114); mean nadir haemoglobin value was 			 6.9 ± 1.7g/dl (median 7.2) versus 8.7 ± 2.3g/dl (median 8; 			 P = 0.009); and mean nadir leucocyte count was 6.2 ± 			 4.1 × 109/l versus 10.2 ± 4.9 × 109/l 			 (P &lt; 0.0004) in cases and control patients, respectively. Nineteen 			 cases (52.7%) and eight control patients (22.2%) had evidence of DIC 			 (P &lt; 0.01).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>12411</offset><text>Closeness of matching</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12433</offset><text>The median age of the cases was 65 years (range 27⌓104 years, mean 			 60.7 years) versus 65 years (range 27⌓83 years, mean 60.6 years) for control 			 patients. Twenty-one (58%) case-control pairs differed by no more than 3 years, 			 and 27 (75%) by no more than 5 years (Table 1). The 			 median APACHE II score of cases was 21 (range 5⌓41, mean 20.8) versus 21 for 			 control patients (range 4⌓37, mean 22.7). The median duration of ICU stay of 			 cases was 5 days (range 1⌓35 days, mean 8.3 days) versus 4 days for control 			 patients (range 1⌓26 days, mean 6.4 days). Thirty-five (97%) of the pairs were 			 matched for primary diagnosis. Overall, matching was successful for 243 out of 			 288 (84.3%) variables.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13168</offset><text>Because the study end point ⌔ mortality ⌔ is strongly related to 			 severity of illness and/or initial respiratory status, we controlled matching by 			 comparing another seven criteria that evaluated the severity of disease in the 			 two groups of patients (Table 2). No significant 			 differences in these indices were observed between cases and control patients. 			 This was particularly the case when comparing the four variables that were 			 individually predictive of survival for all patients: mean SAPS II score, mean 			 number of organ-system failures, number of patients with cardiac failure on 			 admission, and number of patients with renal failure on admission. The sex 			 ratio of the two groups was also similar. Finally, the dates of admission of 			 cases and control patients differed by less than 1 year in 27 pairs (75%).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>14022</offset><text>Mortality</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14032</offset><text>Seventeen (47%) cases died, versus 10 (28%) control patients (Table 3). Twenty-seven matched pairs had a concordant outcome 			 (18 lived and nine died). Nine pairs had a discordant outcome, and in eight of 			 these pairs the case died (exact binomial probabilities: 0.037). The estimated 			 attributable mortality was 19.5% (95% CI 3.2⌓35.8), and the estimated odds 			 ratio was 2.7 (95% CI 1.02⌓7.10).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14443</offset><text>Primary diagnosis in the nine discordant case-control pairs was 			 septic shock in six pairs, acute pancreatitis in one pair, undetermined shock 			 in one pair and haemorrhagic shock in one pair. Causes of mortalities included 			 refractory septic shock in eight cases (47%) and four control patients (40%); 			 multiple organ failure-related sepsis in five cases (29%) and three control 			 patients (30%); uncontrolled bleeding in four cases (24%) and two control 			 patients (20%); and one undetermined shock in one contol (10%).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14980</offset><text>Sensitivity analyses were done to explore whether mortality risk 			 varies according to exposure. Thus, 17 cases experienced a thrombocytopenia 			 below 50 × 109 platelets/l for more than 3 days. Mortality rate 			 was 47%, versus 53 in patients without a prolonged thrombocytopenia (not 			 significant). Likewise, among the 16 cases transfused with platelets, eight 			 died (50%) compared with nine (45%) cases who were not transfused (not 			 significant). A last sensitivity analysis was done on the timing variable. In 			 15 cases, thrombocytopenia occurred more than 2 days after ICU admission. 			 Mortality rate was 65% in these patients compared with 35% in cases in whom 			 thrombocytopenia occurred 2 days or less after ICU admission (P 			  = 0.008).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15749</offset><text>Two time-point analyses of illness severity scores in the nine 			 discordant pairs showed that the APACHE II, SAPS II and ODIN model scores were 			 significantly higher for cases than for control patients on the day of 			 thrombocytopenia (Table 4). Moreover, cases had 			 comparable values of severity of illness scores between day of admission and 			 day of thrombocytopenia; this was contrary to the situation with control 			 patients, who had a statistically significant decrease in severity of illness 			 scores during the same period (Table 4).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>16307</offset><text>Blood product consumption</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16333</offset><text>Thirty (83%) cases required transfusion of blood products, versus 21 			 (58%) control patients (Table 5). Thirteen pairs had 			 discordant transfusion requirements, and in 11 of these pairs the cases were 			 transfused (paired χ2 4.92, P &lt; 0.04). The estimated 			 attributable transfusion requirement was 25% (95% CI 5.4⌓44.6), and the 			 estimated odds ratio was 1.52 (95% CI 1.05⌓2.20).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16732</offset><text>Units of RBCs transfused were 8.0 ± 7.0 (median 7.5) versus 			 2.6 ± 4.3 (median 1.5; P &lt; 0.0001), and units of fresh frozen 			 plasma transfused were 5.0 ± 7.0 (median 1.0) versus 1.0 ± 2.0 (median 			 0; P = 0.05) in cases and control patients, respectively. Sixteen cases 			 (44.4%) received platelet transfusion (5.3 ± 7.7 units of platelets 			 transfused), versus no control patients. In eight patients (one died), platelet 			 transfusions resulted in a rise of platelet count to greater than 			 50 × 109/l, with a correction of thrombocytopenia a few days 			 later. In eight patients (seven died), only a transient rise of platelet count 			 was noted and thrombocytopenia persisted during the entire ICU stay, despite 			 platelet transfusion. After onset of thrombocytopenia, 4.4 ± 7.2 units of 			 RBCs and 2.5 ± 5.4 units of fresh frozen plasma were transfused. This 			 represents about 50% of the total transfusion requirements.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>17688</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>17699</offset><text>The present results suggest that thrombocytopenia of less than 		  50×109platelets/l in ICU patients is associated with increased 		  mortality, with a relative risk of 2.7 (95%CI 1.02-7.10), and with excess blood 		  product consumption, with a relative risk of 1.52 (95%CI 1.05-2.20).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>17987</offset><text>The incidence rate of thrombocytopenia reported in the present study 		  (12% surgical ICU patients) is in the range reported in previous studies. There are many explanations for the 		  thrombocytopenia observed in the context of infection. DIC, immune mechanisms, and 		  haemophagocytic histiocytes are the commonest mechanisms of increased platelet 		  destruction during bacterial infection. In critically ill surgical patients, 		  blood loss with subsequent volume replacement using crystalloids or colloids, 		  when sufficiently severe, can significantly decrease the platelet count. Likewise, a fall in platelet count has been noted after 		  blood transfusions, and the incidence of thrombocytopenia has been specifically 		  reported to be directly proportional to the number of RBC transfusions.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>18796</offset><text>Patients with more severe underlying illness are more likely to 		  develop thrombocytopenia, and the severity of underlying illness has an important 		  impact on the outcome of ICU patients with severe thrombocytopenia. As previously suggested, mortality 		  appears to be proportional to the nadir platelet count. Relatively 		  old studies reported that thrombocytopenia was associated with an 		  increased mortality rate in septic patients. Recent studies using multivariate 		  analysis have reported conflicting results, however. Sprung et al, in a large prospective study, identified 		  thrombocytopenia (&lt; 100 × 109 platelets/l) as an independent 		  predictor of poor prognosis in septic patients, corresponding to a relative 		  risk of death of 1.66 (95%CI 1.06⌓2.60). In a recent multicenter prospective 		  study, Brun-Buisson et al also reported a 		  relative risk of late mortality of 1.5 (95% CI 1.2⌓2.0) in severely ill septic 		  thrombocytopenic patients (platelet count &lt; 50 × 109/l). 		  Another smaller study showed comparable results in 		  septic patients. On the other hand, Pittet et al did not identify thrombocytopenia as an independent 		  predictor of mortality at the onset of sepsis in ICU patients, like 		  Brun-Buisson et al did for early 		  mortality. Finally, when the entire cohort of ICU patients was studied, 		  thrombocytopenia was not identified as a variable that was independently 		  associated with death in two studies. These discrepencies may be attributable to differences in 		  the variables and analytical methods used, and could also result from the 		  complex interactions noted in multivariate analysis.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>20468</offset><text>Case⌓control studies require a considerably smaller sample size than 		  the corresponding longitudinal studies, and is as effective as the cohort study 		  as a basis for causal inference. Critical to the 		  validity of this study is the success in matching cases and control patients 		  for important confounding variables, especially the severity of underlying 		  illness. We used three variables that are strongly correlated with outcome in 		  patients admitted to ICUs to match cases and control patients: age, a severity of disease 		  scoring system (APACHE II), and specific diagnostic categories according to the 		  one main reason for admission. Matching was 84.3% successful for 288 possible 		  variables. To verify the adequacy of matching for severity of underlying 		  illness and primary diagnosis independently, we compared the cases and control 		  patients with respect to another seven potentially confounding variables. No 		  statistically significant differences in these indices were observed between 		  cases and control patients. It may be argued that we matched patients at the 		  time of admission. We realize that this does not reflect the severity of 		  illness at the time of thrombocytopenia, and that matching on variables 		  recorded at the time or just before the diagnosis of thrombocytopenia may have 		  yielded different results. The reliability of systems such as APACHE II, SAPS 		  II and ODIN is not sufficiently defined to study the daily probability of 		  death, however. Moreover, thrombocytopenia is linked to admission 		  characteristics and/or diagnosis, because nearly 60% of patients with 		  thrombocytopenia occurred during the first 2 days after ICU admission.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>22196</offset><text>We found that severe thrombocytopenia is associated with increased 		  mortality, mainly in septic patients, thereby confirming the results of 		  previous cohort studies. In the ICU setting, however, thrombocytopenia is a 		  symptom that has been associated with several acute diseases. It is therefore difficult to distinguish causes from 		  consequences of severe thrombocytopenia clearly in critically ill patients. For 		  example, it is difficult to state that bleeding not represent the results of 		  thrombocytopenia rather than the cause. Although matched case-control studies 		  are attractive because matching assumes comparability for certain variables, 		  the finding of a higher mortality in cases compared with in control patients 		  only implies an association between mortality and thrombocytopenia. Thus, the 		  present analysis identified an increased difference in severity of illness 		  scores between cases and control patients between the day of admission and the 		  day of thrombocytopenia. The finding that illness severity decreased over time 		  in control patients, but remained constant in the cases, supports the notion 		  that severe thrombocytopenia probably largely reflects the unfavourable course 		  of the underlying disease and possibly the aggravating role of thrombocytopenia 		  itself. Thrombocytopenia lasting for less than 3 days confers a similar risk to 		  that of thrombocytopenia for many days. As the present results show, platelet 		  transfusion failed to restore a normal platelet count, but normalization of 		  platelet count, when it occured, was associated with better prognosis, as 		  previously reported.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>23871</offset><text>Patients who require intensive platelet support frequently have 		  complex medical problems, including DIC, clinical bleeding and uncontrolled 		  sepsis. Patients in this setting receive multiple drugs and frequent blood 		  product transfusions. Patients with thrombocytopenia secondary to sepsis often 		  require platelet transfusions, although their response is often suboptimal 		  because of continued platelet destruction, reflecting the persistance of the 		  underlying disease. Likewise, in patients receiving massive transfusion, 		  thrombocytopenia is due both to consumption of platelets and to dilution by 		  transfused blood and colloid fluid resuscitation. These patients may also have 		  platelet function defects due to DIC, hypothermia and 'stunned' 		  recently transfused platelets. Patients may remain midly thrombocytopenic for 		  several days before having a rebound thrombocytosis. Of interest, the mortality impact of thrombocytopenia 		  occurred during the first 2 days after ICU admission, which is quite different 		  from late-onset ICU-acquired thrombocytopenia. This result is in agreement with 		  a previous analysis that indicated that late 		  mortality is essentially associated with the characteristics of the underlying 		  disease.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>25150</offset><text>The mechanism of increased mortality directly related to 		  thrombocytopenia is difficult to assess, but several points should be 		  considered. First, the present results show that severely thrombocytopenic 		  patients required more blood product transfusions. In addition to the possible 		  volume overload, higher postoperative infection rates have been reported in 		  patients who received blood transfusions. Another 		  study, however, did not confirm this relationship. 		  Second, platelets play key and multifactorial roles in antimicrobial host 		  defences. For example, in the absence of 		  neutropenia, thrombocytopenia has been positively correlated with an increased 		  incidence and severity of pneumonia in elderly patients. Third, cases had a lower nadir haemoglobin value than 		  control patients. Two recent studies have shown that patients with a cardiovascular diagnosis and a 		  high degree of acute illness appear to be at increased risk of death from a 		  moderate degree of anaemia. Finally, severe thrombocytopenia is an important 		  risk factor for spontaneous intracerebral haemorrhage associated with a high 		  mortality in critically ill patients.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>26341</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>26352</offset><text>The present report shows that thrombocytopenia of less than 		  50×109platelets/l is associated with excess mortality that is 		  independent of the patient's age and initial severity of illness, and 		  leads to excess blood product consumption, thus imposing a significant economic 		  burden. Thrombocytopenia appears to be mostly a marker of severity of 		  underlying processes, rather than causally related to death. Thus, the exact 		  relationship between thrombocytopenia and mortality has yet to be elucidated, 		  especially in septic patients. Further studies of the specific role of 		  thrombocytopenia in shock and infections are necessary. Moreover, the risks and 		  benefits of the various strategies for the management of thrombocytopenic ICU 		  patients should be reevaluated in a variety of clinical settings.</text></passage><passage><infon key="fpage">1243</infon><infon key="lpage">1247</infon><infon key="name_0">surname:Baughman;given-names:RP</infon><infon key="name_1">surname:Lower;given-names:EE</infon><infon key="name_2">surname:Flessa;given-names:HC</infon><infon key="name_3">surname:Tollerud;given-names:DJ</infon><infon key="pub-id_pmid">8404200</infon><infon key="section_type">REF</infon><infon key="source">Chest</infon><infon key="type">ref</infon><infon key="volume">104</infon><infon key="year">1993</infon><offset>27185</offset><text>Thrombocytopenia in the intensive care unit.</text></passage><passage><infon key="fpage">285</infon><infon key="lpage">289</infon><infon key="name_0">surname:Hanes;given-names:SD</infon><infon key="name_1">surname:Quarles;given-names:DA</infon><infon key="name_2">surname:Boucher;given-names:BA</infon><infon key="pub-id_pmid">9066932</infon><infon key="section_type">REF</infon><infon key="source">Ann Pharmacother</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">1997</infon><offset>27230</offset><text>Incidence and risk factors of thrombocytopenia in critically ill 			 trauma patients.</text></passage><passage><infon key="fpage">1363</infon><infon key="lpage">1370</infon><infon key="name_0">surname:Stéphan;given-names:F</infon><infon key="name_1">surname:Hollande;given-names:J</infon><infon key="name_2">surname:Richard;given-names:O</infon><infon key="pub-id_pmid">10334154</infon><infon key="section_type">REF</infon><infon key="source">Chest</infon><infon key="type">ref</infon><infon key="volume">115</infon><infon key="year">1999</infon><offset>27316</offset><text>Thrombocytopenia in a surgical intensive care unit: incidence, risk 			 factors and outcome.</text></passage><passage><infon key="fpage">1638</infon><infon key="lpage">1652</infon><infon key="name_0">surname:Marshall;given-names:JC</infon><infon key="name_1">surname:Cook;given-names:DJ</infon><infon key="name_2">surname:Christou;given-names:NV</infon><infon key="pub-id_pmid">7587228</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">1995</infon><offset>27409</offset><text>Multiple organ dysfunction score: a reliable descriptor of a complex 			 clinical outcome. </text></passage><passage><infon key="fpage">801</infon><infon key="lpage">806</infon><infon key="name_0">surname:Sprung;given-names:CL</infon><infon key="name_1">surname:Peduzzi;given-names:PN</infon><infon key="name_2">surname:Shatney;given-names:CH</infon><infon key="pub-id_pmid">2379391</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med </infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">1990</infon><offset>27501</offset><text>Impact of encephalopathy on mortality in the sepsis syndrome.</text></passage><passage><infon key="fpage">245</infon><infon key="lpage">246</infon><infon key="name_0">surname:Lee;given-names:KH</infon><infon key="name_1">surname:Hui;given-names:KP</infon><infon key="name_2">surname:Tan;given-names:WC</infon><infon key="pub-id_pmid">8266183</infon><infon key="section_type">REF</infon><infon key="source">Singapore Med J</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">1993</infon><offset>27563</offset><text>Thrombocytopenia in sepsis: a predictor of mortality in the 			 intensive care unit.</text></passage><passage><infon key="fpage">344</infon><infon key="lpage">355</infon><infon key="name_0">surname:Kreger;given-names:BE</infon><infon key="name_1">surname:Craven;given-names:DE</infon><infon key="name_2">surname:McCabe;given-names:WR</infon><infon key="pub-id_pmid">6987871</infon><infon key="section_type">REF</infon><infon key="source">Am J Med</infon><infon key="type">ref</infon><infon key="volume">68</infon><infon key="year">1980</infon><offset>27648</offset><text>Gram-negative bacteria. Re-evaluation of clinical features and 			 treatment in 612 patients.</text></passage><passage><infon key="fpage">732</infon><infon key="lpage">747</infon><infon key="pub-id_pmid">8659805</infon><infon key="section_type">REF</infon><infon key="source">Anesthesiology</infon><infon key="type">ref</infon><infon key="volume">84</infon><infon key="year">1996</infon><offset>27742</offset><text>Practice guidelines for blood component therapy. A report by the 			 American Society of Anesthesiologists task force on blood component 			 therapy.</text></passage><passage><infon key="fpage">1055</infon><infon key="lpage">1060</infon><infon key="name_0">surname:Carson;given-names:JL</infon><infon key="name_1">surname:Duff;given-names:A</infon><infon key="name_2">surname:Poses;given-names:RM</infon><infon key="pub-id_pmid">8874456</infon><infon key="section_type">REF</infon><infon key="source">Lancet </infon><infon key="type">ref</infon><infon key="volume">348</infon><infon key="year">1996</infon><offset>27892</offset><text>Effect of anemia and cardiovasular disease on surgical mortality and 			 morbidity.</text></passage><passage><infon key="fpage">1618</infon><infon key="lpage">1623</infon><infon key="name_0">surname:Hébert;given-names:PC</infon><infon key="name_1">surname:Wells;given-names:G</infon><infon key="name_2">surname:Tweeddale;given-names:M</infon><infon key="pub-id_pmid">9154866</infon><infon key="section_type">REF</infon><infon key="source">Am J Respir Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">155</infon><infon key="year">1997</infon><offset>27976</offset><text>Does transfusion practice affect mortality in critically ill 			 patients? </text></passage><passage><infon key="fpage">951</infon><infon key="lpage">970</infon><infon key="name_0">surname:Yeaman;given-names:MR</infon><infon key="pub-id_pmid">9402338</infon><infon key="section_type">REF</infon><infon key="source">Clin Infect Dis</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">1997</infon><offset>28052</offset><text>The role of platelets in antimicrobial host defense.</text></passage><passage><infon key="fpage">189</infon><infon key="lpage">206</infon><infon key="name_0">surname:Svanbom;given-names:M</infon><infon key="pub-id_pmid">7433919</infon><infon key="section_type">REF</infon><infon key="source">Scand J Infect Dis</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">1980</infon><offset>28105</offset><text>A prospective study on septicemia. Clinical manifestations and 			 complications, results of antimicrobial treatment and report of a follow-up 			 study.</text></passage><passage><infon key="fpage">968</infon><infon key="lpage">274</infon><infon key="name_0">surname:Brun-Buisson;given-names:C</infon><infon key="name_1">surname:Doyon;given-names:F</infon><infon key="name_2">surname:Carlet;given-names:J</infon><infon key="pub-id_pmid">7674528</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">274</infon><infon key="year">1995</infon><offset>28259</offset><text>Incidence, risk factors, and outcome of severe sepsis and septic 			 shock in adults. A multi-center prospective study in intensive care units. </text></passage><passage><infon key="fpage">402</infon><infon key="lpage">406</infon><infon key="name_0">surname:Kitchens;given-names:CS</infon><infon key="pub-id_pmid">9372026</infon><infon key="section_type">REF</infon><infon key="source">Curr Opin Hematol</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">1995</infon><offset>28404</offset><text>Disseminated intravascular coagulation. </text></passage><passage><infon key="fpage">847</infon><infon key="lpage">855</infon><infon key="name_0">surname:McCabe;given-names:WR</infon><infon key="name_1">surname:Jackson;given-names:GC</infon><infon key="section_type">REF</infon><infon key="source">Arch Intern Med</infon><infon key="type">ref</infon><infon key="volume">110</infon><infon key="year">1962</infon><offset>28445</offset><text>Gram-negative bacteria. I. Etiology and ecology.</text></passage><passage><infon key="fpage">137</infon><infon key="lpage">144</infon><infon key="name_0">surname:Fagon;given-names:J-Y</infon><infon key="name_1">surname:Chastre;given-names:J</infon><infon key="name_2">surname:Novara;given-names:A</infon><infon key="name_3">surname:Medioni;given-names:P</infon><infon key="name_4">surname:Gibert;given-names:C</infon><infon key="section_type">REF</infon><infon key="source">Intens Care Med</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">1993</infon><offset>28494</offset><text>Characterization of intensive care unit patients using a model based 			 on the presence or absence of organ dysfunctions and/or infection: the ODIN 			 model.</text></passage><passage><infon key="fpage">818</infon><infon key="lpage">829</infon><infon key="name_0">surname:Knaus;given-names:WA</infon><infon key="name_1">surname:Draper;given-names:EA</infon><infon key="name_2">surname:Wagner;given-names:DP</infon><infon key="name_3">surname:Zimmerman;given-names:JE</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">1985</infon><offset>28654</offset><text>APACHE II: a severity of disease classification system.</text></passage><passage><infon key="fpage">2957</infon><infon key="lpage">2963</infon><infon key="name_0">surname:Le;given-names:Gall J-R</infon><infon key="name_1">surname:Lemeshow;given-names:S</infon><infon key="name_2">surname:Saulnier;given-names:F</infon><infon key="pub-id_pmid">8254858</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">270</infon><infon key="year">1993</infon><offset>28710</offset><text>A new simplified acute physiology score (SAPS II) based on a 			 European/North American multi-center study.</text></passage><passage><infon key="fpage">864</infon><infon key="lpage">874</infon><infon key="name_0">surname:American;given-names:College of Chest Physicians/Society of Critical Care Medicine
				  Consensus Committee</infon><infon key="pub-id_pmid">1597042</infon><infon key="section_type">REF</infon><infon key="source">Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">1992</infon><offset>28819</offset><text>Definitions for sepsis and organ failures and guidelines for the use 			 of innovative therapies in sepsis.</text></passage><passage><infon key="fpage">578</infon><infon key="lpage">590</infon><infon key="name_0">surname:Towsend;given-names:TR</infon><infon key="section_type">REF</infon><infon key="source">Prevention and Control of Nosocomial Infections. Edited by
			 Wenzel RP. Baltimore: Williams and Wilkins</infon><infon key="type">ref</infon><infon key="year">1987</infon><offset>28927</offset><text>New aspects of case-control studies and clinical trials.</text></passage><passage><infon key="name_0">surname:Kirkwood;given-names:BR</infon><infon key="section_type">REF</infon><infon key="source">Essential of Medical Statistics Cambridge, MA: Blackwell
			 Scientific Publications;</infon><infon key="type">ref</infon><infon key="year">1988</infon><offset>28984</offset></passage><passage><infon key="fpage">1690</infon><infon key="lpage">1691</infon><infon key="name_0">surname:Zhang;given-names:J</infon><infon key="name_1">surname:Yu;given-names:KF</infon><infon key="pub-id_pmid">9832001</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">280</infon><infon key="year">1998</infon><offset>28985</offset><text>What's the relative risk? A method of correcting the odds 			 ratio in cohort studies of common outcomes.</text></passage><passage><infon key="fpage">217</infon><infon key="lpage">233</infon><infon key="name_0">surname:Wilson;given-names:JJ</infon><infon key="name_1">surname:Neame;given-names:PB</infon><infon key="name_2">surname:Kelton;given-names:JG</infon><infon key="section_type">REF</infon><infon key="source">Semin Thromb Hemostas</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">1982</infon><offset>29091</offset><text>Infection-induced thrombocytopenia.</text></passage><passage><infon key="fpage">114</infon><infon key="lpage">120</infon><infon key="name_0">surname:François;given-names:B</infon><infon key="name_1">surname:Trimoreau;given-names:F</infon><infon key="name_2">surname:Vignon;given-names:P</infon><infon key="pub-id_pmid">9274894</infon><infon key="section_type">REF</infon><infon key="source">Am J Med</infon><infon key="type">ref</infon><infon key="volume">103</infon><infon key="year">1997</infon><offset>29127</offset><text>Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis 			 and macrophage colony-stimulating factor.</text></passage><passage><infon key="fpage">1159</infon><infon key="lpage">1164</infon><infon key="name_0">surname:Stéphan;given-names:F</infon><infon key="name_1">surname:Thiolière;given-names:B</infon><infon key="name_2">surname:Verdy;given-names:E</infon><infon key="name_3">surname:Tulliez;given-names:M</infon><infon key="pub-id_pmid">9402376</infon><infon key="section_type">REF</infon><infon key="source">Clin Infect Dis</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">1997</infon><offset>29239</offset><text>Role of hemophagocytic histiocytosis in the etiology of 			 thrombocytopenia in patients with sepsis syndrome or septic shock.</text></passage><passage><infon key="fpage">131</infon><infon key="lpage">140</infon><infon key="name_0">surname:Spiess;given-names:BD</infon><infon key="section_type">REF</infon><infon key="source">Post anesthesia Care. Edited by Vender JS, Spiess BD.
			 Philadelphia: WB Saunders;</infon><infon key="type">ref</infon><infon key="year">1992</infon><offset>29366</offset><text>Hemorrhagic problems during the immediate postoperative period.</text></passage><passage><infon key="fpage">211</infon><infon key="lpage">214</infon><infon key="name_0">surname:Oppenheimer;given-names:L</infon><infon key="name_1">surname:Hryniuk;given-names:WM</infon><infon key="name_2">surname:Bishop;given-names:AJ</infon><infon key="pub-id_pmid">1263485</infon><infon key="section_type">REF</infon><infon key="source">J Surg Res</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">1976</infon><offset>29430</offset><text>Thrombocytopenia in severe bacterial infections.</text></passage><passage><infon key="fpage">684</infon><infon key="lpage">693</infon><infon key="name_0">surname:Pittet;given-names:D</infon><infon key="name_1">surname:Thiévent;given-names:B</infon><infon key="name_2">surname:Wenzel;given-names:RP</infon><infon key="pub-id_pmid">8564118</infon><infon key="section_type">REF</infon><infon key="source">Am J Respir Crit Care Med</infon><infon key="type">ref</infon><infon key="volume">153</infon><infon key="year">1996</infon><offset>29479</offset><text>Bedside prediction of mortality from bacteremic sepsis. A dynamic 			 analysis of ICU patients. </text></passage><passage><infon key="fpage">65</infon><infon key="lpage">76</infon><infon key="name_0">surname:Austin;given-names:H</infon><infon key="name_1">surname:Hill;given-names:HA</infon><infon key="name_2">surname:Flanders;given-names:D</infon><infon key="name_3">surname:Greenberg;given-names:RS</infon><infon key="pub-id_pmid">7925729</infon><infon key="section_type">REF</infon><infon key="source">Epidemiol Rev</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">1994</infon><offset>29576</offset><text>Limitations in the application of case-control methodology.</text></passage><passage><infon key="fpage">817</infon><infon key="lpage">874</infon><infon key="name_0">surname:Schroeder;given-names:ML</infon><infon key="section_type">REF</infon><infon key="source">Wintrobe's Clinical Hematology. Edited by Lee GR,
			 Foerster J, Lukens J, et al. Baltimore: Williams and Wilkin;</infon><infon key="type">ref</infon><infon key="year">1998</infon><offset>29636</offset><text>Principles and practice of transfusion medicine. </text></passage><passage><infon key="fpage">659</infon><infon key="lpage">661</infon><infon key="name_0">surname:Edna;given-names:TH</infon><infon key="name_1">surname:Bjerkeset;given-names:T</infon><infon key="pub-id_pmid">1464912</infon><infon key="section_type">REF</infon><infon key="source">J Trauma</infon><infon key="type">ref</infon><infon key="volume">33</infon><infon key="year">1992</infon><offset>29686</offset><text>Association between blood transfusion and infection in injured 			 patients.</text></passage><passage><infon key="fpage">150</infon><infon key="lpage">156</infon><infon key="name_0">surname:Vamvakas;given-names:EC</infon><infon key="name_1">surname:Moore;given-names:SB</infon><infon key="name_2">surname:Cabanela;given-names:M</infon><infon key="pub-id_pmid">7825211</infon><infon key="section_type">REF</infon><infon key="source">Transfusion</infon><infon key="type">ref</infon><infon key="volume">35</infon><infon key="year">1995</infon><offset>29763</offset><text>Blood transfusion and septic complications after hip replacement 			 surgery.</text></passage><passage><infon key="fpage">265</infon><infon key="lpage">270</infon><infon key="name_0">surname:Feldman;given-names:C</infon><infon key="name_1">surname:Kallenbach;given-names:JM</infon><infon key="name_2">surname:Levy;given-names:H</infon><infon key="pub-id_pmid">1792415</infon><infon key="section_type">REF</infon><infon key="source">Respiration</infon><infon key="type">ref</infon><infon key="volume">58</infon><infon key="year">1991</infon><offset>29841</offset><text>Comparison of bacteraemic community-acquired lobar pneumonia due to 			 Streptococcus pneumoniae and Klebsiella pneumoniae in an 			 intensive care unit.</text></passage><passage><infon key="fpage">63</infon><infon key="lpage">67</infon><infon key="name_0">surname:Oppenheim-Eden;given-names:A</infon><infon key="name_1">surname:Glantz;given-names:L</infon><infon key="name_2">surname:Eidelman;given-names:LA</infon><infon key="name_3">surname:Sprung;given-names:CL</infon><infon key="section_type">REF</infon><infon key="source">Intens Care Med</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">1999</infon><offset>29995</offset><text>Spontaneous intracerebral hemorrhage in critically ill patients: 			 incidence over six years and associated factors.</text></passage><passage><infon key="section_type">FIG</infon><infon key="type">title_1</infon><offset>30113</offset><text>Figures and Tables</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>30132</offset><text>Results of matching of cases to control patients using four major
			 criteria</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;Proportion of cases matched to control patients&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td colspan=&quot;2&quot;&gt;&lt;hr/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Criterion&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;n/n&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Same primary diagnosis&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;35/36&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;97&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Same duration of stay in ICU (± 5 days)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;31/36&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;86&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Same APACHE II score (± 5)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;29/36&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;81&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Same age (± 5 years)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;27/36&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;75&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>30211</offset><text>	Proportion of cases matched to control patients	 			 	Criterion	n/n	%	 	Same primary diagnosis	35/36	97	 	Same duration of stay in ICU (± 5 days)	31/36	86	 	Same APACHE II score (± 5)	29/36	81	 	Same age (± 5 years)	27/36	75	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>30443</offset><text>APACHE, Acute Physiology and Chronic Health Evaluation; ICA,
				intensive care unit.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>30529</offset><text>Matching criteria and clinical characteristics of the study
			 population</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;Cases&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Control patients&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Parameter&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 36)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;(&lt;italic&gt;n&lt;/italic&gt; = 36)&lt;/td&gt;&lt;td&gt;&lt;italic&gt;P&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Matching criteria&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;     Primary diagnosis&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;0.99&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Septic shock [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12 (33)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12 (33)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Postoperative bleeding, gastrointestinal
					 hemorrhage, trauma [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;14 (39)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13 (36)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Acute respiratory failure [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3 (8)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3 (8)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Complication during post partum [&lt;italic&gt;n&lt;/italic&gt;
					 (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (6)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (6)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Cardiac failure [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (6)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Miscellaneous [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;sup&gt;*&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (11)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;4 (11)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;    Duration of stay in ICU (days)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;8.3± 8.4&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;6.5± 6.4&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.29&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;    APACHE II score (points)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;22.7± 8.6&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;20.9± 8.3&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.35&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;    Age (years)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;60.7± 19.1&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;60.6± 17.4&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.97&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Characteristics&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;    Sex (male/female)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;20/16&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;22/14&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.63&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;    Severity of underlying disease&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;0.81&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Fatal or ultimately fatal [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;19 (53)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18 (50)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Nonfatal [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17 (47)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;18 (50)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;    Previous health status&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;0.80&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        No functional or moderate limitation [&lt;italic&gt;n&lt;/italic&gt;
					 (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25 (69)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;26 (72)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Serious limitation or bedridden or
					 institutionalized [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;11 (31)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10 (28)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;    SAPS II score (points)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;49.7 ± 18.9&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;46.7 ± 21.9&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.54&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;    Expected mortality (%)&lt;sup&gt;†&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;46.0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;39.1&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;⌓&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;    ODIN model on admission&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td align=&quot;center&quot;&gt;⌓&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Cardiac failure [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;22 (61)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;21 (58)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Respiratory failure [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;30 (83)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;30 (83)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Haematologic failure [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;20 (55)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;13 (36)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Neurologic failure [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;6 (17)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10 (28)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Hepatic failure [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1 (3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2 (5)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;        Presence of infection [&lt;italic&gt;n&lt;/italic&gt; (%)]&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;19 (53)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;16 (44)&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Total no. of organ system failure&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2.8 ± 1.2&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;2.9 ± 1.2&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.60&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>30604</offset><text>	Cases	Control patients		 	Parameter	(n = 36)	(n = 36)	P	 	Matching criteria				 	     Primary diagnosis			0.99	 	        Septic shock [n (%)]	12 (33)	12 (33)		 	        Postoperative bleeding, gastrointestinal	 	      hemorrhage, trauma [n (%)]	14 (39)	13 (36)		 	        Acute respiratory failure [n (%)]	3 (8)	3 (8)		 	        Complication during post partum [n	 	      (%)]	2 (6)	2 (6)		 	        Cardiac failure [n (%)]	1 (3)	2 (6)		 	        Miscellaneous [n (%)]*	4 (11)	4 (11)		 	    Duration of stay in ICU (days)	8.3± 8.4	6.5± 6.4	0.29	 	    APACHE II score (points)	22.7± 8.6	20.9± 8.3	0.35	 	    Age (years)	60.7± 19.1	60.6± 17.4	0.97	 	Characteristics				 	    Sex (male/female)	20/16	22/14	0.63	 	    Severity of underlying disease			0.81	 	        Fatal or ultimately fatal [n (%)]	19 (53)	18 (50)		 	        Nonfatal [n (%)]	17 (47)	18 (50)		 	    Previous health status			0.80	 	        No functional or moderate limitation [n	 	      (%)]	25 (69)	26 (72)		 	        Serious limitation or bedridden or	 	      institutionalized [n (%)]	11 (31)	10 (28)		 	    SAPS II score (points)	49.7 ± 18.9	46.7 ± 21.9	0.54	 	    Expected mortality (%)†	46.0	39.1	⌓	 	    ODIN model on admission			⌓	 	        Cardiac failure [n (%)]	22 (61)	21 (58)		 	        Respiratory failure [n (%)]	30 (83)	30 (83)		 	        Haematologic failure [n (%)]	20 (55)	13 (36)		 	        Neurologic failure [n (%)]	6 (17)	10 (28)		 	        Hepatic failure [n (%)]	1 (3)	2 (5)		 	        Presence of infection [n (%)]	19 (53)	16 (44)		 	Total no. of organ system failure	2.8 ± 1.2	2.9 ± 1.2	0.60	 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>32375</offset><text>*Miscellaneous included two cases of nosocomial
				pneumonia, one case of acute pancreatitis, and one case of undetermined shock.
				†Calculated from the equation proposed by La Gall et al. APACHE, Acute Physiology and Chronic Health Evaluation;
				ODIN, organ dysfunstion and/or infection; ICU, intensive care unit; SAP,
				Simplified Acute Physiology Score.</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>32741</offset><text>Crude mortality, attributable mortality, and odds ratio of death due
			 to severe thrombocytopenia in intensive care unit patients</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;Point estimate&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td colspan=&quot;2&quot;&gt;&lt;hr/&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Variable&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;n&lt;/italic&gt;/&lt;italic&gt;n&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;%&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;95% CI&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Crude mortality (cases)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;17/36&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;47.2&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Crude mortality (control patients)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;10/36&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;27.8&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Attributable mortality&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;7/36&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;19.4&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3.2⌓35.8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Odds ratio&lt;/td&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;2.7&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.02⌓7.10&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>32873</offset><text>	Point estimate		 				 	Variable	n/n	%	95% CI	 	Crude mortality (cases)	17/36	47.2		 	Crude mortality (control patients)	10/36	27.8		 	Attributable mortality	7/36	19.4	3.2⌓35.8	 	Odds ratio	2.7	1.02⌓7.10	 	</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>33084</offset><text>CI, confidence interval.</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>33109</offset><text>Comparison of illness severity scores between cases and control
			 patients on the day of admission and on the day of onset of thrombocytopenia in
			 the nine discordant pairs</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Score&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Cases (&lt;italic&gt;n&lt;/italic&gt; = 9)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;Control patients (&lt;italic&gt;n&lt;/italic&gt; = 9)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;P&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;APACHE II (median)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; Day of admission&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25.2 ± 4.2 (25)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;24.0 ± 6.7 (26)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; Day of thrombocytopenia&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;30.7 ± 8.3 (47)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12.9 ± 5.2 (11)*&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.04&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;SAPS II (median)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; Day of admission&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;46.6 ± 10.5 (47)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;46.9 ± 16.9 (40)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; Day of thrombocytopenia&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;58 ± 18.2 (51)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;32.1 ± 10.4 (31)*&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.04&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ODIN model (median)&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; Day of admission&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3.3 ± 1.4 (4)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3.0 ± 1.0 (3)&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;NS&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; Day of thrombocytopenia&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;3.8 ± 0.67&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.7 ± 1 (0)*&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;0.008&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Expected mortality (%)&lt;sup&gt;†&lt;/sup&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; Day of admission&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;39.1&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;39.1&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;⌓&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; Day of thrombocytopenia&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;64.0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;12.8&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;⌓&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>33287</offset><text>Score	Cases (n = 9)	Control patients (n = 9)	P	 	APACHE II (median)				 	 Day of admission	25.2 ± 4.2 (25)	24.0 ± 6.7 (26)	NS	 	 Day of thrombocytopenia	30.7 ± 8.3 (47)	12.9 ± 5.2 (11)*	0.04	 	SAPS II (median)				 	 Day of admission	46.6 ± 10.5 (47)	46.9 ± 16.9 (40)	NS	 	 Day of thrombocytopenia	58 ± 18.2 (51)	32.1 ± 10.4 (31)*	0.04	 	ODIN model (median)				 	 Day of admission	3.3 ± 1.4 (4)	3.0 ± 1.0 (3)	NS	 	 Day of thrombocytopenia	3.8 ± 0.67	0.7 ± 1 (0)*	0.008	 	Expected mortality (%)†				 	 Day of admission	39.1	39.1	⌓	 	 Day of thrombocytopenia	64.0	12.8	⌓	 	</text></passage><passage><infon key="file">T4.xml</infon><infon key="id">T4</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>33892</offset><text>*P &lt; 0.05 by Wilcoxon's signed-rank
				test (score on day of admission versus score on day of thrombocytopenia in
				control group). †Calculated from the equation proposed by Le
				Gall et al..</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>34091</offset><text>Crude transfusion requirements, attributable transfusion
			 requirements, and odds ratio of transfusion requirements due to severe
			 thrombocytopenia in intensive care unit patients</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;Point estimate&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td colspan=&quot;2&quot;&gt;&lt;hr/&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Variable&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;italic&gt;n/n&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;%&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;95% Cl&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Crude transfusion requirements&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; Cases&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;30/36&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;83.0&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt; Control patients&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;21/36&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;58.0&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Attributable transfusion&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;9/36&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;25.0&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;5.4⌓44.6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;requirements&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Odds ratio&lt;/td&gt;&lt;td align=&quot;center&quot; colspan=&quot;2&quot;&gt;1.52&lt;/td&gt;&lt;td align=&quot;center&quot;&gt;1.05⌓2.20&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>34276</offset><text>	Point estimate		 				 	Variable	n/n	%	95% Cl	 	Crude transfusion requirements				 	 Cases	30/36	83.0		 	 Control patients	21/36	58.0		 	Attributable transfusion	9/36	25.0	5.4⌓44.6	 	requirements				 	Odds ratio	1.52	1.05⌓2.20	 	</text></passage><passage><infon key="file">T5.xml</infon><infon key="id">T5</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>34514</offset><text>CI, confidence interval.</text></passage></document></collection>
